Symbols

ACHL(Delisted)

Achilles·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ACHL

Achilles Therapeutics Plc

A British biotech company that develops precise T-cell therapies for solid tumors

Industry

Established Date

Listing Date

03/31/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

215

Fiscal Year Ends

12-31

Website

www.achillestx.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

245 Hammersmith Road, London W6 8PW, United Kingdom

Business

Introduction

Achilles Therapeutics plc was incorporated under the laws of England and Wales in May 2016. They are a clinical-stage immuno-oncology biopharmaceutical company developing translatable precision T-cell therapies to treat multiple types of solid tumors.

Company Financials

EPS

ACHL has released its 2024 Q3 earnings. EPS was reported at -0.48, versus the expected -0.41, missing expectations. The chart below visualizes how ACHL has performed over recent quarters, highlighting trends in earnings surprises.